Similarly for the pan-Akt inhibitor, MK2206, studies [21, 22] have demonstrated that treatment with this drug induced G0/G1-phase arrest which was associated with a marked decrease in cyclin D1 levels in hepatocellular carcinoma HepG2 cells. Here, AKT1 is linked to hepatocellular carcinoma.